CMND

Clearmind Medicine Inc

Mar 17 • 04:00PM ET

0.7500

+0.0100 1.35 %

Healthcare • Biotechnology • Canada • NASD

Mar 17, 9:20 AMClearmind Medicine announces six Hong Kong patents for Palmitoylethanolamide-based combination therapies with MDMA, LSD, ketamine, ibogaine, psilocybin and DMT

Peers: ATAI DFTX HELP GHRS EOLS RLMD RLAY CMPS FLNA TCRT

| Held by: PSIL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-24.14	Insider Own	26.37%	Shs Outstand	1.50M	Perf Week	-25.00%
Market Cap	1.57M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.06M	Perf Month	-33.04%
Enterprise Value	-8.77M	PEG	-	EPS next Q	-	Inst Own	8.40%	Short Float	171.77%	Perf Quarter	-74.76%
Income	-6.64M	P/S	-	EPS this Y	-	Inst Trans	-0.68%	Short Ratio	0.44	Perf Half Y	-98.17%
Sales	0.00M	P/B	0.14	EPS next Y	-	ROA	-74.91%	Short Interest	0.10M	Perf YTD	-58.56%
Book/sh	5.49	P/C	0.15	EPS next 5Y	-	ROE	-119.72%	52W High	52.40 -98.57%	Perf Year	-98.36%
Cash/sh	4.94	P/FCF	-	EPS past 3/5Y	83.49% 39.75%	ROIC	-80.60%	52W Low	0.70 7.32%	Perf 3Y	-99.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	18.91% 11.54%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	54.05%	Oper. Margin	-	ATR (14)	0.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.79	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	22.86	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	3.79	EPS Q/Q	65.27%	SMA20	-29.56%	Beta	-0.96	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-55.76%	Rel Volume	2.90	Prev Close	0.74
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	-96.83%	Avg Volume	232.51K	Price	0.75
IPO	Aug 16, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	674,918	Change	1.35%

Mar-17-26 09:15AM	Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies (GlobeNewswire)
Mar-16-26 07:30AM	NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy (NewMediaWire) -5.13%
Mar-13-26 07:45AM	Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy (GlobeNewswire) -5.88%
Mar-11-26 09:07AM	Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results (GlobeNewswire) -6.28%
07:30AM	NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease (NewMediaWire)
08:59AM	Loading…
Mar-10-26 08:59AM	Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease (GlobeNewswire)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks) +5.56%
Mar-04-26 07:30AM	Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval (GlobeNewswire)
Feb-19-26 01:05PM	Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss? (PR Newswire)
Feb-16-26 02:58PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Feb-09-26 08:17AM	Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial (GlobeNewswire) -8.15%
Feb-08-26 03:50PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Feb-06-26 07:55AM	Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI (GlobeNewswire) -6.90%
Feb-03-26 08:00AM	Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments (GlobeNewswire) -5.83%
Jan-20-26 04:20PM	Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 (GlobeNewswire) +5.60%
08:55AM	Loading…
Jan-14-26 08:55AM	Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 (GlobeNewswire)
Dec-31-25 09:10AM	Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Dec-24-25 09:15AM	Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth (GlobeNewswire) -5.76%
Dec-16-25 08:45AM	Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 (GlobeNewswire)
Dec-15-25 08:03AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -8.48%
Dec-12-25 08:32AM	Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment (GlobeNewswire)
06:32AM	Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement (GlobeNewswire)
Dec-10-25 04:15PM	Clearmind Medicine Announces 1-for-40 Reverse Share Split (GlobeNewswire) -6.08% -37.27%
Dec-05-25 05:00PM	Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
Dec-02-25 07:57AM	Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire) -9.94%
Dec-01-25 08:56AM	Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial (GlobeNewswire) -6.92%
Nov-25-25 07:17AM	Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial (GlobeNewswire) -19.40%
Nov-24-25 08:51AM	Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review (GlobeNewswire) +8.41%
Nov-23-25 01:22PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-20-25 06:01AM	Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site (GlobeNewswire)
10:35AM	Loading…
Nov-19-25 10:35AM	Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression (NewMediaWire) -6.42%
Nov-18-25 08:56AM	Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire) -21.85%
Nov-17-25 07:55AM	Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression (GlobeNewswire)
Nov-13-25 08:54AM	Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center (GlobeNewswire) +11.57%
Nov-12-25 06:25AM	Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment (GlobeNewswire) -32.32%
Nov-10-25 08:07AM	Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Nov-06-25 04:02PM	Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency (GlobeNewswire) -5.75% -7.70%
Nov-05-25 06:55AM	Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing (GlobeNewswire)
Nov-02-25 04:32PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-31-25 07:35AM	Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy (GlobeNewswire) -12.28%
Oct-30-25 07:55AM	Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire) -9.30%
Oct-28-25 08:08AM	Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar (GlobeNewswire)
Oct-27-25 09:22AM	Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement (GlobeNewswire)
Oct-21-25 07:25AM	Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Oct-20-25 07:41AM	Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders (GlobeNewswire) +11.71%
Sep-25-25 07:40AM	Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies (GlobeNewswire)
Sep-19-25 08:20AM	Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities (GlobeNewswire) +19.00%
Aug-07-25 07:32AM	SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar (GlobeNewswire) +6.23%
07:32AM	Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar (GlobeNewswire)
Aug-05-25 08:15AM	Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center (GlobeNewswire)
Jul-30-25 08:18AM	Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease (GlobeNewswire)
08:12AM	SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease (GlobeNewswire)
Jul-23-25 08:55AM	Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder (GlobeNewswire)
Jul-20-25 07:00PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-15-25 08:05AM	Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled (GlobeNewswire)
Jul-09-25 06:15AM	Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck (GlobeNewswire) -6.42%
Jul-03-25 08:47AM	Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center (GlobeNewswire) +21.82%
Jun-30-25 09:16AM	Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Jun-28-25 09:10AM	Clearmind Medicine expands global clinical trial targeting AUD market (TipRanks)
Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
09:00AM	Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market (GlobeNewswire)
Jun-25-25 07:48AM	Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment (GlobeNewswire)
Jun-24-25 08:06AM	Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics (GlobeNewswire)
Jun-23-25 07:55AM	Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
Jun-12-25 09:25AM	Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics (GlobeNewswire)
Jun-05-25 07:32AM	Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment (GlobeNewswire)
May-20-25 09:00AM	Clearmind Medicine to Host Live Webinar "Gazing Through the Crystal Ball" Featuring Leading Psychedelic Experts (GlobeNewswire)
May-12-25 07:32AM	Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction (GlobeNewswire)
Apr-25-25 11:30AM	Psychedelic: Clearmind completes clinical site initiations for AUD trial (TipRanks)
07:59AM	SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders (GlobeNewswire)
07:55AM	Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders (GlobeNewswire)
Apr-23-25 08:25AM	Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites (GlobeNewswire)
Apr-21-25 09:15AM	Clearmind Medicine to Host Live Webinar Gazing Through the Crystal Ball Featuring Leading Psychedelic Experts (GlobeNewswire) -6.25%
Apr-17-25 07:38AM	Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior (GlobeNewswire) +15.46%
Apr-16-25 08:40AM	Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism (GlobeNewswire) +5.43%
Apr-11-25 11:05AM	Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial (TipRanks)
Apr-10-25 08:25AM	Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder (GlobeNewswire)
Apr-08-25 06:55AM	Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders (GlobeNewswire)
Apr-01-25 08:15AM	Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment (GlobeNewswire)
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
09:28AM	Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones (GlobeNewswire)
Mar-19-25 07:35AM	Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination (GlobeNewswire)
Mar-18-25 07:32AM	Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients (GlobeNewswire) +5.26%
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks)
Mar-10-25 07:45AM	SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea (GlobeNewswire) +8.49%
07:27AM	Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea (GlobeNewswire)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-04-25 09:00AM	SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico (GlobeNewswire)
08:35AM	Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico (GlobeNewswire)
Jan-07-25 09:28AM	Clearmind Medicine Announces Shareholders Meeting Results (GlobeNewswire) -5.70%
Jan-06-25 08:15AM	Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment (GlobeNewswire) +6.04%
07:50AM	SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment (GlobeNewswire)
Jan-02-25 07:45AM	Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office (GlobeNewswire) +5.07%
Dec-27-24 07:05AM	Clearmind Medicine to move forward with MEAI-based alcohol substitute (TipRanks)
Dec-26-24 06:59AM	Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute (GlobeNewswire) -9.30%
Dec-24-24 06:55AM	Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial (GlobeNewswire) +40.98%
Dec-16-24 08:37AM	Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal Format (GlobeNewswire) -11.08%

Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMND

Clearmind Medicine Inc

Upgrade your FINVIZ experience